Dr. Andreadis is on Doximity
As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
505 Parnassus Ave
San Francisco, CA 94143Phone(415) 476-4029
Fax(415) 353-2467- Is this information wrong?
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology/Oncology, 2001 - 2005
New York Presbyterian HospitalResidency, Internal Medicine, 1998 - 2001
Columbia University College of Physicians & SurgeonsClass of 1998
Certifications & Licensure
CA State Medical License 2008 - 2021
NY State Medical License 2004 - Present
PA State Medical License 2001 - 2008- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Protein Expression in Diffuse Large B-Cell Lymphoma Start of enrollment: 2016 May 01Charalambos Andreadis, MD, MSCE
- Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML Start of enrollment: 2014 Jan 01Andreadis, C.
- Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2012 Jun 01Andreadis, C.,Pelle-Day, G.
- A Phase I Dose Finding and Proof-of-concept Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Combination With Standard Dose Cytarabine and Daunorubicin for Older Patients With Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Start of enrollment: 2012 Jan 01Andreadis, C.I.
- Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Post-remission Chemotherapy for Leukemia Start of enrollment: 2011 Mar 01Vinh, N., Copelan, E., Salman, H.
- A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients With Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation Start of enrollment: 2009 Nov 01Martin, T.
- Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck Start of enrollment: 2008 Mar 01Andreadis, C.
- Join now to see all
Publications & Presentations
PubMed
- High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomasLi-Wen Huang, Dong Sun, Thomas M. Link, Thomas Lang, Weiyun Z. Ai, Lawrence D. Kaplan, Michael A. Steinman, Charalambos Andreadis> ;Supportive Care in Cancer. 2021 Mar 10
- The role of acalabrutinib in adults with chronic lymphocytic leukemia.Bita Fakhri, Charalambos Andreadis> ;Therapeutic advances in hematology. 2021 Feb 5
- Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures.J. Bodden, Dong Sun, Gabby B. Joseph, Li-Wen Huang, Charalambos Andreadis, Millie Hughes-Fulford, Thomas Lang, Thomas M. Link> ;Osteoporosis International. 2021 Feb 1
- Join now to see all
Abstracts/Posters
- A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin LymphomaCharalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Ofatumumab, Etoposide and Cytarabine Intensive Mobilization Regimen in Patients with High-Risk Relapsed/Refractory Diffuse Large B-cell Lymphoma Undergoing Autologous Stem Cell TransplantationNovember 10th, 2020
AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences ConferenceApril 1st, 2019- Novel Oral TKI in Chronic Leukemia Requires Genetic Testing, Adherence to TherapyMay 31st, 2015
- Join now to see all
Other Languages
- Greek
Hospital Affiliations
UCSF Medical CenterSan Francisco, California
Zuckerberg San Francisco General Hospital and Trauma CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
